Specify a stock or a cryptocurrency in the search bar to get a summary
Genenta Science SpA ADR
GNTAGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. Address: Via Olgettina No. 58, Milan, MI, Italy, 20132
Analytics
WallStreet Target Price
23 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures GNTA
Dividend Analytics GNTA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GNTA
Stock Valuation GNTA
Financials GNTA
Results | 2019 | Dynamics |